Drug Profile
Levodopa/carbidopa - RVL Pharmaceuticals
Alternative Names: OS-353Latest Information Update: 21 Jan 2022
Price :
$50
*
At a glance
- Originator Osmotica Pharmaceutical
- Developer RVL Pharmaceuticals
- Class Antiasthmatics; Antiparkinsonians; Aromatic amino acids; Catecholamines; Hydrazines; Small molecules
- Mechanism of Action Decarboxylase inhibitors; Dopamine receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Parkinson's disease
Most Recent Events
- 19 Jan 2022 Osmotica Pharmaceuticals is now called RVL Pharmaceuticals
- 01 Oct 2014 Discontinued - Phase-II for Parkinson's disease in Argentina (unspecified route)
- 02 Nov 2012 Phase-III clinical trials in Parkinson's disease in USA (unspecified route)